NEUES VERFAHREN

European patent · EP2571902 · In force

Register entry

Publication number
EP2571902
Application number
EP11721756
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
May 18, 2011
Published
Mar 27, 2013
Granted
Jul 10, 2019
Protection ends at the latest
May 17, 2031
Next annual fee due
May 31, 2026
IPC classes
C08B 37/00 (2006.01)
C12P 19/04 (2006.01)
Priority
GB 201008401 20.05.2010
PCT application
PCT/EP2011/058016 18.05.2011
PCT publication
WO2011/144645 24.11.2011
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Jun 1, 2025

    Change

    Published in Swissreg on 01.06.2025

  2. Jun 2, 2024

    Change

    Published in Swissreg on 02.06.2024

  3. Jun 1, 2023

    Change

    Published in Swissreg on 01.06.2023

  4. Sep 5, 2019

    Agent entered

    Representative
    Isler & Pedrazzini AG, Postfach 1772, 8027 Zürich

    Published in Swissreg on 05.09.2019

  5. Jul 10, 2019

    Granted

    Published in Swissreg on 10.07.2019

Parties

Holder

GlaxoSmithKline Biologicals S.A.

Rue de l'Institut, 89, 1330 Rixensart, BE

Agent

Isler & Pedrazzini AG

Postfach 1772, 8027 Zürich

Inventor

MANCUSO, Vincent

B-1330 Rixensart, BE

GELDHOF, Geoffroy

B-1330 Rixensart, BE

CHARLES, Philippe

B-1330 Rixensart, BE

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.